secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2025-06-02T23:59:59+00:00
Accession:  0001193125-25-132760
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kymera reports positive Phase 1 data for oral STAT6 degrader KT-621; >90% STAT6 degradation at low doses
--------------------------------------------------------------------------------

- SAD: >90% mean STAT6 degradation in blood at doses starting at 6.25 mg; ≥75 mg achieved complete degradation.
- MAD: complete STAT6 degradation in blood and skin at doses ≥50 mg; safety undifferentiated from placebo with no SAEs.
- Th2 biomarkers: median TARC -37%, Eotaxin-3 -63% at Day 14, comparable or superior to dupilumab in healthy volunteers.
- KT-621 well-tolerated: no TRAEs in >1 subject, no severe AEs, no discontinuations, no clinically relevant lab/ECG changes.
- Next steps: Phase 1b AD data Q4 2025; Phase 2b AD start Q4 2025, asthma Q1 2026, enabling parallel Phase 3 readiness.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000119312525132760/0001193125-25-132760-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000119312525132760/d57872d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-132760

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer